Pentoxifylline-d6

Modify Date: 2024-01-09 19:21:02

Pentoxifylline-d6 Structure
Pentoxifylline-d6 structure
Common Name Pentoxifylline-d6
CAS Number 1185878-98-1 Molecular Weight 284.34400
Density N/A Boiling Point N/A
Molecular Formula C13H12D6N4O3 Melting Point N/A
MSDS N/A Flash Point N/A

 Use of Pentoxifylline-d6


Pentoxifylline-d6 (BL-191-d6) is the deuterium labeled Pentoxifylline. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation[1][2][3].

 Names

Name 1-(5-oxohexyl)-3,7-bis(trideuteriomethyl)purine-2,6-dione
Synonym More Synonyms

 Pentoxifylline-d6 Biological Activity

Description Pentoxifylline-d6 (BL-191-d6) is the deuterium labeled Pentoxifylline. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation[1][2][3].
Related Catalog
In Vitro Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

[2]. Iffat Hassan, et al. Pentoxifylline and its applications in dermatology. Indian Dermatol Online J. 2014 Oct-Dec; 5(4): 510–516.

[3]. A Ward, et al. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs. 1987 Jul;34(1):50-97.

[4]. Yessica Cristina Castellanos-Esparza, et al. Synergistic promoting effects of pentoxifylline and simvastatin on the apoptosis of triple-negative MDA-MB-231 breast cancer cells. Int J Oncol. 2018 Apr;52(4):1246-1254.

[5]. Shabnam Movassaghi, et al. Effect of Pentoxifylline on Ischemia- induced Brain Damage and Spatial Memory Impairment in Rat. Iran J Basic Med Sci. 2012 Sep-Oct; 15(5): 1083-1090.

 Chemical & Physical Properties

Molecular Formula C13H12D6N4O3
Molecular Weight 284.34400
Exact Mass 284.17600
PSA 78.89000
LogP 0.19300
Storage condition 2-8°C

 Synthetic Route

~15%

Pentoxifylline-d6 Structure

Pentoxifylline-d6

CAS#:1185878-98-1

Literature: US2009/239886 A1, ; Page/Page column 27-28 ; US 20090239886 A1

~%

Pentoxifylline-d6 Structure

Pentoxifylline-d6

CAS#:1185878-98-1

Literature: WO2011/28835 A1, ;

~%

Pentoxifylline-d6 Structure

Pentoxifylline-d6

CAS#:1185878-98-1

Literature: WO2011/28835 A1, ;

 Synonyms

Oxpentifylline-d6
Vazofirin-d6
Pentoxifylline-d6
3,7-di(methyl-d3)-1-(5-oxohexyl)-1H-purine-2,6(3H,7H)-dione
1-(5-Oxohexyl)-3,7-(dimethyl-d6)xanthine-d6
3,7-Dihydro-3,7-(dimethyl-d6)-1-(5-oxohexyl)-1H-purine-2,6-dione
Trental-d6
1-(5-Oxohexyl)theobromine-d6